Stockscreener 앱 받기
10.92
10.27%
-1.25
시장 영업 전:
11.51
0.59
+5.40%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Using data filters to optimize entry into REGENXBIO Inc.Analyst Upgrade & Weekly Return Optimization Plans - newser.com
Price momentum metrics for REGENXBIO Inc. explained2025 Performance Recap & Technical Pattern Alert System - newser.com
Market reaction to REGENXBIO Inc.’s recent newsQuarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com
What does recent volatility data suggest for REGENXBIO Inc.Trade Analysis Report & Consistent Profit Focused Trading Strategies - newser.com
REGENXBIO (NASDAQ:RGNX) CEO Curran Simpson Sells 20,811 Shares - MarketBeat
Insider Sell: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Regenxbio CEO Simpson Curran sells $262,634 in stock - Investing.com
Chart based analysis of REGENXBIO Inc. trendsWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
REGENXBIO (NASDAQ:RGNX) Reaches New 12-Month HighTime to Buy? - MarketBeat
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - Eastern Progress
Why REGENXBIO Inc. is moving todayWeekly Profit Report & Long-Term Safe Return Strategies - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Is REGENXBIO Inc. trending in predictive chart modelsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
How to build a dashboard for REGENXBIO Inc. stockEarnings Summary Report & Free Real-Time Market Sentiment Alerts - newser.com
How cyclical is REGENXBIO Inc. (RB0) stock compared to rivalsJuly 2025 Market Mood & Safe Entry Trade Reports - newser.com
REGENXBIO, Inc. Hits New 52-Week High at $12.30 - Markets Mojo
2-Year Results: REGENXBIO Presents ALTITUDE Phase II Data for Diabetic Retinopathy Oct 17 - Stock Titan
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29% - simplywall.st
Is REGENXBIO Inc. stock positioned for digital transformationTrade Risk Report & Reliable Entry Point Alerts - newser.com
Is REGENXBIO Inc. (RB0) stock a top hedge fund pickTrade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
REGENXBIO (NASDAQ:RGNX) Trading 9.1% HigherShould You Buy? - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
REGENXBIO's (RGNX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates REGENXBIO (RGNX) Buy Recommendation - Nasdaq
Regenxbio stock maintains Buy rating at H.C. Wainwright on gene therapy potential - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for RGNX with $34 Targ - GuruFocus
Viral Vector Gene Therapy Market Size Expects to Reach USD 38.39 Billion by 2034 - GlobeNewswire Inc.
Regenxbio Inc. Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet Amd - MarketScreener
REGENXBIO completes enrollment in wet AMD gene therapy trials - Investing.com
RGNX Completes Enrollment for Key Macular Degeneration Studies - GuruFocus
REGENXBIO completes enrollment in wet AMD gene therapy trials By Investing.com - Investing.com Nigeria
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for wet AMD - MarketScreener
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD - TradingView
1,200+ Enrolled: REGENXBIO Completes Largest Gene Therapy Wet AMD Program; Topline Q4 2026 - Stock Titan
What indicators show strength in REGENXBIO Inc.2025 Trading Recap & Low Risk High Win Rate Picks - newser.com
Combining price and volume data for REGENXBIO Inc.2025 Fundamental Recap & Expert Curated Trade Setup Alerts - newser.com
Will REGENXBIO Inc. stock gain from lower inflation2025 Performance Recap & Technical Pattern Based Signals - newser.com
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
Is REGENXBIO Inc a good long term investmentTechnology Stock Trends & Superior Capital Investment - earlytimes.in
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
REGENXBIO Inc. $RGNX Shares Sold by Voya Investment Management LLC - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Curran Simpson Sells 7,624 Shares of REGENXBIO (NASDAQ:RGNX) Stock - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares - Investing.com
5.74%
자본화:
|
볼륨(24시간):